Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

KBA vs SBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SBIO Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

SBIO Overall Winner 6-Pillar Tally: KBA 0 – 0 SBIO (6 Tie) Matrix Metrics: KBA 1 – 2 SBIO

As of Nov 17, 2026, ALPS Medical Breakthroughs ETF (SBIO) is the stronger overall head-to-head candidate over KraneShares Bosera MSCI China A 50 Connect Index ETF (KBA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). KBA carries a Unified Composite Score of 43.7/100 (HOLD) at $27.78 (N/M Forward P/E, N/A operating margin), whereas SBIO carries 46.4/100 (HOLD) at $53.87 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: KBA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.6); meanwhile SBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KBA vs SBIO
KBA NYSE Arca
KraneShares Bosera MSCI China A 50 Connect Index ETF
Institutional Equity
$27.78
-0.18% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.86β · 19% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 38.0 Fund 49.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.7%), weak momentum, RSI 34
RSI-14: 33.6 · SMA20: $28.59 · SMA50: $30.22
SBIO NYSE Arca Head-to-Head Winner
ALPS Medical Breakthroughs ETF
Institutional Equity
$53.87
-3.17% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.21β · 44% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 48.0 Fund 51.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.3%), weak momentum, RSI 44
RSI-14: 44.2 · SMA20: $55.23 · SMA50: $57.04

6-Pillar Scorecard Institutional Category Breakdown (KBA 0 – 0 SBIO)

Columns: Metric · KBA · SBIO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 37.1% (23rd %ile) 42.3% (6th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KBA (1) vs SBIO (2)
Institutional Metric KBA SBIO Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
0% ($28–$35) 35% ($45–$71) Stronger Trend SBIO
Beta / 30D Volatility
Risk Regime
0.86β · 19% Vol 1.21β · 44% Vol Lower Realized Risk KBA
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 46.4 / 100 (HOLD) Higher Composite SBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SBIO +13.14 pp
KBA: -5.66% · SBIO: +7.48%
3M Horizon KBA +4.66 pp
KBA: -17.37% · SBIO: -22.03%
6M Horizon SBIO +21.33 pp
KBA: -16.85% · SBIO: +4.48%
1Y Horizon SBIO +24.48 pp
KBA: -7.64% · SBIO: +16.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KBA vs SBIO. Trailing 12-month operating profitability (KBA N/A vs SBIO N/A) and valuation multiples (KBA N/M vs SBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

KBA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KBA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 37.1%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KBA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KBA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SBIO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KBA vs SBIO Key Questions & Quantitative Answers

As of Nov 17, 2026, ALPS Medical Breakthroughs ETF (SBIO) is the stronger overall head-to-head candidate over KraneShares Bosera MSCI China A 50 Connect Index ETF (KBA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). KBA carries a Unified Composite Score of 43.7/100 (HOLD) at $27.78 (N/M Forward P/E, N/A operating margin), whereas SBIO carries 46.4/100 (HOLD) at $53.87 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: KBA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.6); meanwhile SBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KBA and SBIO split Growth & Scale metrics: KBA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SBIO at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, KBA generates N/A in USD-normalized revenue versus N/A for SBIO. In operating R&D and SG&A reinvestment, KBA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SBIO.

KBA and SBIO trade at balanced relative valuation multiples. KBA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KBA (N/A ROE) versus SBIO (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, KBA carries 37.1% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.86β · 19% Vol realized risk). By comparison, SBIO carries 42.3% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.21β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.